Alentis Therapeutics
Developing breakthrough treatments for cancer and fibrotic disease
Alentis is a clinical stage Swiss-French biotech company, spun out of the University of Strasbourg. Alentis develops breakthrough treatments for Claudin 1 (CLDN1) positive tumors. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering anti-CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
Alentis was founded in 2018 and was financed, incubated and built in close collaboration between Prof. Thomas Baumert, the scientific founder of Alentis and the team of BaseLaunch. The work culminated in Alentis raising a Series A in early 2019, co-led by Pureos Bioventures, BioMedPartners, and BPI, and subsequent B, C and D rounds bringing the total raise to USD 366M
”There is no other incubator like BaseLaunch and Alentis would not exist without it. BaseLaunch has backed us in critical times and was invaluable on all aspects of getting the company launched, being it on licensing our IP, helping assemble the initial team or supporting our series A financing. To this day, from time to time we still make use of their support and incredible network.
Thomas BaumertFounder and Executive BoD